INTRODUCTION
Continuous and rapid advances in tumor biology, drug discovery and immunotherapy are accelerating the adoption of precision oncology. There is a growing arsenal of targeted therapeutics that disrupt oncogenes and modulate dysregulated molecular pathways [1] . Additionally, a growing subclass of molecularly targeted immunotherapeutics has developed to either stimulate or reduce the inhibition of cytotoxic T-cells [2] [3] [4] . Adoptive T-cell engineering, including chimeric antigen receptor T-cells (CAR-T), is being used to precisely target cancer cells that express specific antigens [5, 6] . Oncolytic viruses are also being engineered to target molecular states of tumor cells [7] . This rapid pace of development has led to a large menu of genomic and transcriptomic alterations that are potentially clinically-relevant for each individual patient. Therefore, well-designed genomic and transcriptomic sequencing panels are necessary for clinical testing [1] .
We previously presented the Tempus xO assay, a next generation sequencing (NGS)-based oncology assay that interrogates 1,711 cancer-related genes in matched tumor and normal tissue with whole transcriptome RNA sequencing (RNA-seq) for gene rearrangement detection [8] . We now present the Tempus xT assay, a more focused targeted oncology panel using hybrid capture NGS to interrogate a refined list of 595 genes (Table 1) , including solid tumor and hematologic malignancy targets selected through extensive review of recent literature and oncogenic pathway analysis (see Methods). The assay also includes a combination of whole transcriptome RNA-Seq and targeted DNA tiling probes (Table 2) for comprehensive gene rearrangement detection, as well as microsatellite instability (MSI) testing. In addition to the clinical testing function of the assay, the DNA-and RNAseq assay components support a combination of research and clinical tools for the evaluation of tumor immunity status, including HLA typing, neoantigen prediction, DNA Research Paper www.oncotarget.com Table 1: xT gene list   ABCB1  ABCC3  ABL1  ABL2  ACTA2  ACVR1B  AJUBA  AKT1  AKT2  AKT3  ALK   AMER1  APC  APOB  AR  ARAF  ARHGAP26 ARHGAP35  ARID1A  ARID1B  ARID2  ARID5B   ASNS  ASXL1  ATIC  ATM  ATP7B  ATR  ATRX  AURKA  AURKB  AXIN1  AXIN2   AXL  B2M  BAP1  BARD1  BCL2  BCL2L1  BCL2L11  BCL6  BCL7A  BCL10  BCL11B   BCLAF1  BCOR  BCORL1  BCR  BIRC3  BLM  BMPR1A  BRAF  BRCA1  BRCA2  BRD4   BRIP1  BTG1  BTK  BUB1B  C3orf70  C8orf34  C10orf54  C11orf30  C11orf65  CALR  CARD11   CASP8  CASR  CBFB  CBL  CBLB  CBLC  CBR3  CCDC6  CCND1  CCND2  CCND3   CCNE1  CD19  CD22  CD40  CD70  CD79A  CD79B  CD274  CDC73  CDH1  CDK4   CDK6  CDK8  CDK12  CDKN1A  CDKN1B  CDKN1C  CDKN2A  CDKN2B  CDKN2C  CEBPA  CEP57   CFTR  CHD2  CHD4  CHEK1  CHEK2  CIC  CIITA  CKS1B  CREBBP  CRKL  CRLF2   CSF1R  CSF3R  CTC1  CTCF  CTLA4  CTNNA1  CTNNB1  CTRC  CUX1  CXCR4  CYLD   CYP1B1  CYP2D6  CYP3A5  DAXX  DDB2  DDR2  DDX3X  DICER1  DIRC2  DIS3  DIS3L2   DKC1  DNM2  DNMT3A  DOT1L  DPYD  DYNC2H1  EBF1  ECT2L  EGF  EGFR  EGLN1   ELF3  ENG  EP300  EPCAM  EPHA2  EPHA7  EPHB1  EPHB2  EPOR  ERBB2  ERBB3   ERBB4  ERCC1  ERCC2  ERCC3  ERCC4  ERCC5  ERCC6  ERG  ERRFI1  ESR1  ETS1   ETS2  ETV1  ETV4  ETV5  ETV6  EWSR1  EZH2  FAM46C  FAM175A  FANCA  FANCB   FANCC  FANCD2  FANCE  FANCF  FANCG  FANCI  FANCL  FANCM  FAS  FAT1  FBXO11   FBXW7  FCGR2A  FCGR3A  FDPS  FGF1  FGF2  FGF3  FGF4  FGF5  FGF6  FGF7   FGF8  FGF9  FGF10  FGF14  FGF23  FGFR1  FGFR2  FGFR3  FGFR4  FH  FHIT   FLCN  FLG  FLT1  FLT3  FLT4  FNTB  FOXA1  FOXL2  FOXO1  FOXO3  FOXP1   FOXQ1  FRS2  FUBP1  G6PD  GALNT12  GATA1  GATA2  GATA3  GATA4  GATA6  GEN1   GLI1  GNA11  GNA13  GNAQ  GNAS  GPC3  GPS2  GREM1  GRIN2A  GRM3  GSTP1   H3F3A  H19  HAS3  HAVCR2  HDAC1  HDAC2  HDAC4  HGF  HIF1A  HIST1H1E  HIST1H3B   HIST1H4E  HLA-A  HLA-B  HLA-C  HLA-DMA HLA-DMB  HLA-DOA  HLA-DOB  HLA-DPA1  HLA-DPB1  HLA-DPB2   HLA-DQA1  HLA-DQA2  HLA-DQB1  HLA-DQB2 HLA-DRA HLA-DRB1  HLA-DRB5 HLA-DRB6  HLA-E  HLA-F  HLA-G   HNF1A  HNF1B  HOXB13  HRAS  HSP90AA1  HSPH1  IDH1  IDH2  IDO1  IFIT1  IFIT2   IFIT3  IFNAR1  IFNAR2  IFNGR1  IFNGR2  IFNL3  IKBKE  IKZF1  IL2RA  IL6R  IL7R   IL10RA  IL15  ING1  INPP4B  IRF1  IRF2  IRF4  IRS2  ITPKB  JAK1  JAK2   JAK3  JUN  KAT6A  KDM5A  KDM5C  KDM6A  KDR  KEAP1  KEL  KIF1B  KIT   KLHL6  KLLN  KMT2A  KMT2B  KMT2C  KMT2D  KRAS  LAG3  LDLR  LEF1  LMNA   LMO1  LRP1B  LYN  LZTR1  MAD2L2  MAF  MAFB  MALT1  MAP2K1  MAP2K2  MAP2K4   MAP3K1  MAP3K7  MAPK1  MAX  MC1R  MCL1  MDM2  MDM4  MED12  MEF2B  MEN1   MET  MGMT  MIB1  MITF  MKI67  MLH1  MLH3  MLLT3  MPL  MRE11A  MS4A1   MSH2  MSH3  MSH6  MTAP  MTHFR  MTOR  MTRR  MUTYH  MYB  MYC  MYCL   MYCN  MYD88  MYH11  NBN  NCOR1  NCOR2  NF1  NF2  NFE2L2  NFKBIA  NHP2   NKX2-1  NOP10  NOTCH1  NOTCH2  NOTCH3  NPM1  NQO1  NRAS  NRG1  NSD1  NT5C2   NTHL1  NTRK1  NTRK2  NTRK3  NUDT15  NUP98  P2RY8  PAK1  PALB2  PALLD  PARK2   PAX3  PAX5  PAX7  PAX8  PBRM1  PCBP1  PDCD1  PDCD1LG2  PDGFRA  PDGFRB  PDK1   PDPK1  PHF6  PHOX2B  PIAS4  PIK3C2B  PIK3CA  PIK3CB  PIK3CD  PIK3CG  PIK3R1  PIK3R2   PIM1  PLCG2  PML  PMS1  PMS2  POLD1  POLE  POLH  POT1  POU2F2  PPP1R15A   PPP2R1A  PPP2R2A  PPP6C  PRCC  PRDM1  PREX2  PRKAR1A  PRSS1  PRSS2  PTCH1  PTCH2   PTEN  PTPN11  PTPN13  PTPN22  PTPRD  QKI  RAC1  RAD21  RAD50  RAD51  RAD51B   RAD51C  RAD51D  RAD54L  RAF1  RANBP2  RARA  RASA1  RB1  RBM10  RECQL4  RET   RHOA  RICTOR  RINT1  RIT1  RNF43  RNF139  ROS1  RPL5  RPS6KB1  RPS15  RPTOR   RSF1  RUNX1  RUNX1T1  RXRA  SCG5  SDHA  SDHAF2  SDHB  SDHC  SDHD  SEC23B   SEMA3C  SETBP1  SETD2  SF3B1  SGK1  SH2B3  SLC26A3  SLC47A2  SLIT2  SLX4  SMAD2   SMAD3  SMAD4  SMARCA1  SMARCA4 SMARCB1  SMARCE1  SMC1A  SMC3  SMO  SOCS1  SOD2   SOX2  SOX9  SOX10  SPEN  SPINK1  SPOP  SPRED1  SRC  SRSF2  STAG2  STAT3   STAT4  STAT5A  STAT5B  STAT6  STK11  SUFU  SUZ12  SYK  TAF1  TANC1  TAP1   TAP2  TBC1D12  TBL1XR1  TBX3  TCF3  TCF7L2  TCL1A  TERT  TET2  TGFBR2  TIGIT   TMEM127  TMEM173  TMPRSS2  TNF  TNFAIP3  TNFRSF9  TNFRSF14  TNFRSF17  TOP1  TOP2A  TP53 repair gene analysis, MSI status, tumor mutational burden, and immune cell typing and expression.
RESULTS
We have instituted performance benchmarks to support the clinical use of the xT assay and have assessed analytical sensitivity, specificity, accuracy and precision across the test's reportable range.
Single nucleotide variant and indel sensitivity, specificity, and limit of detection In order to determine assay sensitivity for single nucleotide variants (SNVs) in solid tumors, a panel of formalin-fixed, paraffin-embedded (FFPE) clinical tumor samples were sequenced and compared against previously reported results from the Tempus xO assay [8] . There were 487 unique SNVs previously detected in the tumor samples, with variant allele fractions (VAFs) from 5% to 100% (median 25.9%). All but four variants were detected in both assays, resulting in a SNV sensitivity of 99.1% (354/357). To categorize sensitivity at low VAFs, reference standards containing variants between 1-30% VAF were used (Horizon Diagnostics, Columbus, GA). This comparison showed a sensitivity of 96.9% (126/130).
Specificity was calculated as the number of bases identified as negative for variation by both the xT assay and orthogonal methodology, divided by the total number of bases called negative by the assay. A total of two false positives were observed resulting in a specificity of >99.9%, with a positive predictive value (PPV) of 99.5% (347/349). The overall precision of the assay was calculated as 97.2%, with a slight dependency on base fraction at the lower limit of detection (LOD) ( Figure 1A,  1B) . Additionally, the correlation of VAF measurements between the xT and xO assays was determined by measuring the correlation coefficient ( Figure 1C, 1D) . The   TP63  TPM1  TPMT  TRAF3  TSC1  TSC2  TSHR  TUSC3  TYMS  U2AF1  UBE2T   UGT1A1  UGT1A9  UMPS  VEGFA  VHL  WEE1  WHSC1  WRN  WT1  XPA  XPC   XPO1  XRCC1  XRCC2  XRCC3  YEATS4  ZFHX3  ZNF217  ZNF471  ZNF620  ZNF750  ZNRF3 ZRSR2 xT assay shows high concordance in base fractions (r 2 = 0.971 for indels, r 2 = 0.921 for SNVs) with the xO assay at all ranges of performance.
Serial dilution of tumor samples with matched normal samples was performed to generate variants with base fractions between 25% and 1% VAF. Three variants were detected using dilutions down to 1.4% VAF (1:16 dilution of a 20% variant in the tumor). One mutation was detected down to an allele fraction of 2.1% (1:8 dilution) but not at the 1:16 dilution ( Figure 1E) . A conservative LOD of 5% was therefore set for SNVs, although we observed consistent detection below that threshold ( Figure  1F ). Indels were consistently detected down to 4% VAF ( Figure 1E) . A conservative LOD of 10% was therefore set for the indels. Fifty indels were called within the xT LOD for 48 samples in the set. Of these 50 indels, 48 were called by xT, and one variant (NOTCH3 p.1317fs) was excluded from analysis due to insufficient coverage on the xT panel. Thus, the final sensitivity calculation was 98.0% (48/49). PPV was calculated using the 49 indels called by the xT assay and their comparison against all xO data. All 49 indels called were concordant with the xO assay. We, therefore, observed a >99.9% PPV for indel detection.
Gene rearrangement and fusion validation
The assay is designed to assess 21 gene rearrangement targets by DNA-seq (Table 2) , in addition to comprehensive fusion detection by RNAseq as previously reported [8] . The reportable range for gene rearrangements by DNA-seq is limited to fusions occurring in the specific regions listed in Table 2 . Twenty-seven validation samples (including 23 patient samples and 4 reference standards) with known gene rearrangements were sequenced. Results were compared with the previously validated RNA-seq fusion detection assay [8] , and the reference standard results were compared with the manufacturer-provided data sheets. The assay successfully detected 28 of the 29 gene rearrangements within the 27 samples. The DNA-seq translocation detection sensitivity was 96.5% (28/29) , with an overall sensitivity of translocation detection, including RNA-seq, of 99.9% (29/29) . The overall distribution of reported gene rearrangements by cancer type for the patient cohort sequenced at Tempus Labs is shown in Figure 2A .
Specificity was analyzed with a subset of 13 samples that were assessed for the absence of additional xT reportable fusions. This was calculated as the number of samples (n = 13) multiplied by the number of assayed genomic sites (n = 21) for 273 positions. The xT assay called zero false positive translocations, resulting in a >99.9% specificity. Furthermore, a positive control fusion monitored by Tempus (ROS1-SLC34A2) in the reference standard (HD753, Horizon Diagnostics) was detected 20 out of 20 times ( Figure 2B ).
To assess the LOD, we used a serial dilution of two known positive control samples (containing ALK-EML4 and ANKRD26-RET, respectively). Samples were diluted from 50-60% VAF in the primary sample to 3-4% VAF ( Figure 2C ). The gene rearrangements were detected in all experiments, but in the case of the two lowest titrations for ALK-EML4, the number of supporting reads fell below the normal reporting threshold for the assay. A conservative LOD was set at 10% based on the ALK-EML4 detection data. Additionally, we functionally characterized clinically relevant fusions detected via the xT assay, such as RET-CCDC6 and TMPRSS2-ERG fusions ( Figure 2D, 2E ).
Copy number alterations
Copy number variation (CNV) is particularly difficult to detect in targeted panels. Paired-end mapping strategies typically fail because the majority of CNV breakpoints occur in non-targeted regions [20] . The depth of coverage is the primary metric used to determine copy number, but variable probe affinities, probe balance, and hybridization produce significant coverage variability [21] . This can be corrected by comparing the tumor sample with its matched normal sample and/or a pool of unrelated normal samples. The xT panel design significantly reduces the number of heterozygous SNVs required to make an Analysis of the recurrent TMPRSS2-ERG fusion found in 13 prostate cancers detected by the xT assay. The xT assay consistently localized breakpoints to the expected functional domains resulting in the TMPRSS2 promoter and replacing the first several exons of ERG by a chromosomal deletion. This results in the functional domains of ERG being largely intact, but under the control of the TMPRSS2 promoter. integrated segmentation call. Accordingly, models used for fitting corrected coverage ratios to potential ploidy and corresponding copy number are selected based not only on goodness-of-fit but also on the resulting genomewide ploidy state [22] . CNV specificity was assessed as the total number of genes assayed (n = 67 patients, 39 genes each) and the number of false positive detections (n = 3). Specificity was calculated as called negatives/true negatives, resulting in a final specificity of 99.8%. PPV was calculated as the total number of amplification calls made by the xT copy number analysis pipeline (n = 70) versus the number of copy number calls that were correctly identified as amplified (n = 67). This latter analysis was performed using CNVs that were clearly amplified in xO (>9 copies), or those identified as amplified in xT, but moderately amplified (>5 copies) in xO. This resulted in a final PPV of 95.7%. To assess LOD, three samples with CNVs in ERBB2, CDK12, or EGFR were diluted between 50% and 5% tumor purity. In all cases, amplified regions were detected and identified as amplified down to at least 12.5% tumor purity. To allow for the detection of lessheavily amplified genetic regions, a lower LOD was set at 30% tumor purity.
Additionally, the National Institutes of Standards and Technology's (NIST) RM 2373 (Genomic DNA Standards for HER2 Measurements) was evaluated for CNVs in ERBB2 (HER2). The copy number results for ERBB2 generated by the xT assay were linear (r 2 =0.97) with respect to the validated copy ratios across the five reference samples ( Figure 3A) . Furthermore, the amplification call crosses the regression line at an ERBB2 ratio of 2.5. In calling ERBB2 positivity in breast cancers using FISH, an ERBB2 ratio of 2.2 was used to call positivity, closely correlating with the assay threshold for amplification calling. The distribution of CNVs by cancer type for the patient cohort sequenced at Tempus Labs is shown in Figure 3B .
Finally, large scale genomic alterations were assessed using the xT assay ( Figure 3C ). Due to the longrange genomic tiling of the xT assay, it was hypothesized that large scale genomic instability might be detectable via chromosome level copy number visualization. For example, in oligodendrogliomas, the xT assay consistently detected the 1p-19q co-deletion, an important diagnostic and prognostic marker. These complex structural alterations were successfully detected with the xT assay although they are not part of the common class of focal alterations reported in the literature from NGS-based tumor profiling methodologies.
Microsatellite instability detection
MSI results from defects in DNA mismatch repair. 
three replicates were sequenced on the same plate for intra-assay precision and three replicates were sequenced on separate plates for inter-assay precision. The accuracy, precision, and LOD were assayed for tumornormal paired and tumor-only samples.
The xT MSI assay was validated against an MSI PCR assay using the five marker Bethesda panel (Arup Laboratories, Salt Lake City, UT), a four-protein MMR immunohistochemistry (IHC) panel (Tempus Labs, Chicago, IL), or both. Samples found to be MSI-H by the MSI PCR, or missing expression in at least one protein by the MMR IHC were collectively considered MSI-H. Similarly, samples found to be MSS by the MSI PCR, or with normal MMR protein expression by the MMR IHC were considered MSS. One sample had contradictory MSI PCR and MMR IHC results and was removed from the study. In both paired and unpaired modes, the 14 MSI-H samples were correctly classified as MSI-H and the 20 MSS samples were correctly classified as MSS, thus, the sensitivity of MSI status determination was >99%, the specificity was >99%, and the PPV was >99%.
To establish the LOD, three MSI-H patient DNA samples were serially diluted to determine the minimum tumor fraction necessary to reliably detect MSI-H status. MSI-H status was consistently detected down to approximately 20% tumor in both the paired and unpaired modes. The LOD was conservatively set at 30% tumor.
Immuno-oncology profiling
Immunotherapy has become a key tool for treating a wide range of cancers. A current challenge in the field is the proper identification of patients most likely to benefit from this powerful but expensive therapy that can also have severe side effects [25] [26] [27] [28] . In the course of clinical care, TMB, Human Leukocyte Antigen (HLA) type, neoantigen load, and MSI status were calculated in order to evaluate the benefits of immunotherapy. HLA genes are involved in the presentation of self-and foreign peptides to T cells. Specific HLA alleles are associated with serious pharmacological counter-indications, eligibility for clinical trials, and increased probability of response or non-response to checkpoint therapy. HLA typing is also a prerequisite for neoantigen prediction. We assessed the accuracy and sensitivity of in silico HLA typing on a set of 72 known reference samples obtained directly from the International Histocompatibility Working Group in Seattle, WA (www.ihwg.org). For reference samples sequenced on the xT panel, class I HLA typing was 99.8% accurate at the two-digit resolution and 96.6% accurate at the four-digit resolution (Supplementary Table 1 ). Sequencing was also sensitive for alleles associated with pharmacological counter-indications and alleles used for inclusion and exclusion criteria in immunotherapy clinical trials (Supplementary Tables 2-3 ). www.oncotarget.com TMB and MSI status was assessed in 806 clinical samples spanning more than 28 different cancer types ( Figure 4) . While predictive power varied with cancer type, the xT assay TMB scoring recapitulated disease-specific TMB estimates previously reported in the literature [29] (Figure 4A) . One of the most well characterized mechanistic drivers of high TMB is MSI-H status. The xT MSI assay showed that MSI-H tumors accounted for 26.6% of tumors in the top decile of TMB, with MSI-H status significantly associated with high TMB (p = 8.72e-26, hypergeometric test). In MSI-H cases, alterations were frequently found in genes encoding DNA mismatch repair (MMR) proteins (MLH1, PMS2, MSH2, and MSH6). In a number of cases where no genetic alterations were found, we were able to detect MLH1 silencing based on reduced RNA expression. The assay also detected an enrichment of alterations in known DNA repair genes, including WRN, RAD50, PMS1, MUTYH, BRCA1, BRCA2, BLM, and ATM ( Figure 4B ).
Pan-cancer molecular profiling
We next analyzed the landscape of genomic alterations in 1074 clinical samples assayed with the xT panel. A subset of samples was optimized to appropriately represent the percentages of cancer types seen in clinical care sites serviced by Tempus Labs. These data were then compared against large-scale genomic profiling efforts [23, 24] to assess the clinical validity of the assay. Within the Tempus cohort, 952 samples contained at least one biologically relevant alteration (88.6%), which was defined as an alteration associated with pathogenicity based on literature, databases, or in silico reviews. The evidence for biological relevance ranges from alterations addressed by the National Comprehensive Cancer Network (NCCN) guidelines with FDA-approved therapeutic interventions, through on and off tissue clinical research, down to preclinical evidence with or without clinical trial eligibility. Within the 952 patients, the most prevalent alterations across cancer types were the tumor suppressor TP53 (57%) and the oncogene KRAS (20%) ( Figure 5A ). Along with these highly prevalent alterations known to be present in an array of cancer types, there were many canonical oncogenic pathway mutations detected, including gain of function mutations in oncogenes (EGFR 11%, PIK3CA 16%) and loss of function mutations in tumor suppressor genes (PTEN 11%, ARID1A 8%, APC 6%) [37, 38, 41] . Furthermore, the localization of variants in recurrently mutated genes showed a strong correlation across cancer types ( Figure 5B ), indicating consistent functional mechanisms for oncogenicity as expected from previous pan-cancer studies [24] .
DISCUSSION
Molecularly targeted therapies, including immunotherapy, are providing better treatment options for cancer patients. To fully utilize these advances, patients must undergo broad molecular tumor profiling for optimal, personalized treatment selection [1] . According to NCCN guidelines, therapy targeted towards specific molecular alterations is already a standard of care in several tumor types, including melanoma, colorectal cancer, and nonsmall cell lung cancer. These few, well-known mutations could be detected with individual assays or small NGS panels. However, for the largest number of patients to benefit from personalized oncology, molecular alterations that can be targeted with off-label drug indications, combination therapy, or tissue agnostic immunotherapy should be assessed [30] [31] [32] . Large-panel NGS assays also cast a wider net for clinical trial enrollment [33, 34] . Recent studies indicate that clinical care is guided by NGS assay results for 30-40% of patients who receive such testing [35] [36] [37] [38] .
We have developed a hybrid capture NGS-based assay to accurately detect clinically relevant alterations across 595 genes that are carefully curated to address solid tumors and hematologic malignancies, plus perform genome-wide unbiased fusion detection. The assay inputs include FFPE tissue, blood or bone marrow tumor specimens, and blood or saliva for germline testing. This assay is unique in its use of matched tumor and normal DNA plus whole transcriptome RNA-seq to provide a comprehensive overview of somatic genomic alterations, including MSI status for targeted cancer therapy, immuno-oncology, and clinical trial enrollment. The test was validated by multiple testing modalities, including a comparison of patient samples to reference assays and pooled cell-line models spanning key determinants of detection accuracy for somatic alterations such as VAF, indel length, the degree of stromal admixture, and amplitude of CNV.
Large NGS panels optimize targeted therapy options because they reveal a wide range of genomic alterations and can be used when working with small FFPE tissue samples. Additionally, broad-based NGS genomic profiling enables patients with rare genomic alterations to be identified for clinical trials. The Tempus xT assay provides the opportunity to deep screen known actionable gene variants and a broad set of biologically relevant cancer-related genes on a clinically validated platform with a relatively rapid turnaround time.
MATERIALS AND METHODS xT assay gene selection
Genes were selected for the xT assay based on recommendations from major professional oncologyrelated societies, including the National Comprehensive Cancer Network (NCCN), the Association for Molecular Pathology (AMP), the College of American Pathologists (CAP), and the American College of Medical Genetics and Genomics (ACMG). An extensive literature review was conducted to include the addition of genes from known oncogenic pathways, particularly those covered in The Cancer Genome Atlas (TCGA) analysis of oncogenic signaling pathways [41] . In this publication, 89% of the 9,125 tumors analyzed contained at least one driver alteration in one of the 10 canonical pathways. Thus, these genes alone account for a substantial number of driver mutations across cancer types. Next, genes from DNA repair, chromatin remodeling, splicing, ubiquitination, and metabolic pathways were included in the assay. Genes associated with treatment resistance and cancer predisposition, including all cancer-associated genes listed as incidental findings by the ACMG, were also included. Additionally, the intronic regions of 21 key genes that undergo clinically relevant gene rearrangements were included for robust fusion detection. Finally, the gene list was reviewed for completeness by experts familiar with the literature and current medical practices for all major tumor types.
Sample processing and nucleic acid extraction
A total of 265 patient samples were processed and used in the validation of this study. Normal blood samples were collected in PAXgene Blood DNA Tubes (Catalog #761115) and saliva samples were collected in Oragene DNA Saliva Kits (Catalog #OG-510). Germline ("normal") DNA was extracted from either 650µl of saliva or 200 µl of blood. After expert pathologist assessment of overall tumor amount and percent tumor cellularity as a ratio of tumor to normal nuclei met a 20% threshold, solid tumor total nucleic acid was extracted from macrodissected FFPE tissue sections and digested by proteinase K. RNA was purified from the total nucleic acid by DNase-I digestion.
Hematologic malignancy samples were collected in EDTA collection tubes. We examined a set of samples collected at Rush University Medical Center (RUMC) that were also analyzed with a Genoptix Myeloid Molecular Panel (Carlsbad, CA) at RUMC. A subset of samples was 
DNA and RNA library construction and sequencing
DNA and RNA sequencing was performed as previously described [8] . Briefly, 100 nanograms (ng) of DNA for each tumor and normal sample was mechanically sheared to an average size of 200 base pairs (bp) using a Covaris ultrasonicator. DNA libraries were prepared using the KAPA Hyper Prep Kit, hybridized to the xT probe set, and amplified with the KAPA HiFi HotStart ReadyMix. One hundred ng of RNA for each tumor sample was heat fragmented in the presence of magnesium to an average size of 200 bp. Library preps were hybridized with the IDT xGEN Exome Research Panel and target recovery was performed using Streptavidin-coated beads, followed by amplification with the KAPA HiFi Library Amplification Kit. The amplified target-captured DNA tumor libraries were sequenced to an average unique on target depth of 500x on an Illumina HiSeq 4000. Samples were further assessed for uniformity with each sample required to have 95% of all targeted bp sequenced to a minimum depth of 300x.
Detection of somatic variants by the xT assay
Tumor and normal FASTQ files were matched to their appropriate pair. FASTQ files were analyzed using FASTQC for rapid assessment of quality control and aligned with Novoalign (Novocraft, Inc.). The SAM files were converted to BAM, BAM files were sorted, and duplicates were marked. Following alignment and sorting, SNVs were called. To assess copy number, de-duplicated BAM files and a VCF generated from the variant calling pipeline were processed for computation of read depth and variation in heterozygous germline SNVs between the tumor and normal samples (or between the tumor sample and a pool of process matched normal controls for tumoronly cases). Circular binary segmentation [9] was applied and segments were selected with highly differential log2 ratios between the tumor and its comparator. Approximate integer copy number was then assessed from a combination of differential coverage in segmented regions and an estimate of stromal admixture generated by analysis of heterozygous germline SNVs.
Detection and visualization of gene rearrangements by the xT assay
Following de-multiplexing, tumor FASTQ files were aligned against the human reference genome using BWA for DNA files, or aligned to GRCh38 using STAR for RNA files [10, 39] . Raw RNA read counts were then normalized to correct for GC content and gene length using full quantile normalization and adjusted for sequencing depth via the size factor method. DNA reads were sorted and duplicates were marked with SAMBlaster [40] . Discordant and split reads were further identified and separated. These data were then read into LUMPY [11] for structural variant detection. Structural alterations were grouped by type, recurrence, and presence within the Tempus database and displayed through the Tempus quality control application (TSQC) fusion tool. The TSQC fusion viewer referenced Ensembl to determine the gene and proximal exons surrounding the breakpoint for any possible transcript generated across the breakpoint. It then placed the breakpoint 5' or 3' to the subsequent exon in the direction of transcription. For inversions, this orientation was reversed for the inverted gene. After positioning of the breakpoint, the translated amino acid sequences were generated for both genes in the chimeric protein, and a plot was generated containing the remaining functional domains for each as returned from Uniprot [12] ( Figure  2D , 2E).
Variant classification and reporting
Variants were investigated following criteria from known evolutionary models, functional data, clinical data, and literature. Variants were then prioritized and classified based on known gene-disease relationships, hotspot regions within genes, internal and external somatic databases, primary literature, and other features of somatic drivers [13, 14, 15] . Variants were reported based on recommendations from the AMP/ASCO/CAP guidelines [16] . Briefly, pathogenic variants with therapeutic, diagnostic, or prognostic significance were prioritized in the report. Non-actionable pathogenic variants were included as biologically relevant, followed by variants of uncertain significance. Translocations were reported based on features of known gene fusions, relevant breakpoints, and biological relevance. Evidence was curated from outside sources and presented as 1) consensus guidelines 2) clinical research, or 3) case studies, with a link to the supporting literature. Germline alterations were reported as secondary findings in a subset of genes for consenting patients. These include genes recommended by the ACMG [17] and additional genes associated with cancer predisposition or drug resistance.
Microsatellite instability status
We developed probes for 43 microsatellite regions for the xT assay. The MSI classification algorithm classifies tumors into three categories: microsatellite instability-high (MSI-H), microsatellite stable (MSS), or microsatellite equivocal (MSE). MSI testing for paired tumor-normal patients used reads mapped to the microsatellite loci with at least five bp flanking the microsatellite. The identification of at least 30 mapping reads in both tumor and normal samples were required for the locus to be included in the analysis. At least 20 of the 43 microsatellites on the panel were required to reach the minimum coverage. Each locus was individually tested for instability, as measured by changes in the number of repeats in tumor data compared to normal data, using the Kolmogorov-Smirnov test. If p ≤ 0.05, the locus was considered unstable. The proportion of unstable microsatellite loci was fed into a logistic regression classifier trained on samples from the TCGA colorectal and endometrial cohorts, which have clinically determined MSI statuses. For MSI testing in tumor-only mode, the mean and variance for the number of repeats were calculated for each microsatellite locus. A vector containing the mean and variance data was put into a support vector machine classification algorithm. Both algorithms returned the probability of the patient being MSI-H. If there was a >70% probability of MSI-H status, the sample was classified as MSI-H. If there was between a 30-70% probability of MSI-H status, the test results were too ambiguous to interpret and those samples were classified as MSE. If there was a <30% probability of MSI-H status, the sample was considered MSS.
Tumor mutational burden
TMB was calculated by dividing the number of non-synonymous mutations by the megabase size of the panel (2.4 MB). All non-silent somatic coding mutations, including missense, indel, and stop-loss variants, with coverage >100x and an allelic fraction >5% were counted as non-synonymous mutations. A TMB >9 mutations per million bp of DNA was considered "high". This threshold was established by hypergeometric testing for the enrichment of tumors with orthogonally defined hypermutation (MSI-H) in the larger Tempus clinical database.
HLA typing
HLA class I typing was performed using Optitype on DNA sequencing including class I HLA-mapped reads and unmapped reads [18] . Normal samples were used as the default reference for matched tumor-normal samples. Tumor sample-determined HLA type was used when the normal sample did not meet internal HLA coverage thresholds, or there was no matched normal sample.
Neoantigen prediction
Neoantigen prediction was performed on all nonsilent mutations. The binding affinities for all possible 8-11 amino acid (aa) peptides containing the mutation were predicted using MHCflurry [19] . For alleles with insufficient training data to generate an allele-specific MHCflurry model, binding affinities were predicted from the nearest HLA allele as assessed by aa homology. A mutation was determined to be antigenic if any resulting peptide was predicted to bind to any of the patient's HLA alleles with <500 nM affinity.
